Seagen and Zai Lab ink part­ner­ship on Tiv­dak ex­pan­sion in­to Chi­na and sur­round­ing ar­eas; NC biotech snaps up seed fund­ing

Zai Lab has signed on to com­mer­cial­ize Seagen and Gen­mab’s Tiv­dak — an ADC for re­cur­rent or metasta­t­ic cer­vi­cal can­cer in pa­tients in which chemother­a­py isn …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER